Navigation Links
R-Tech Ueno Notifies R&D Items
Date:7/30/2009

TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows.

The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities.

1. Development code UF-021 (eye diseases)

The item in question is isopropyl unoproston, the effective ingredient of "Rescula(R) eyedrop 0.12%" that is marketed as a therapeutic drug for glaucoma and ocular hypertension. This drug is now being developed by R-Tech Ueno for the indication of retinitis pigmentosa. The drug is introduced to Sucampo Pharma Americas Ltd. in the USA to be developed for the indication of atrophic age-related macular degeneration.

2. Development code RTU-007 (eye diseases)

The license is obtained from Astellas Pharma Inc. for the substance to inhibit the enzyme that increases in patients with diabetes mellitus. We intend to proceed with the development of this substance to be indicated for diabetic cataract, diabetic retinopathy and age-related macular degeneration.

3. Development code RU-10 (eye diseases)

Dry eye is targeted for development of the drug that contains gene recombination human serum albumin as an effective ingredient. Though the clinical study is currently interrupted, we intend to look for overseas affiliation soon because the need for treatment of dry eye is globally unmet (that is, there are currently few therapeutic drugs).

4. Development code RK-023 (dermatological diseases)

This item is a physiologically active fatty acid derivative that is a new compound developed by R-Tech Ueno and is being developed as a drug indicated for male
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
2. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Boston Scientific Announces First Quarter Special Items
5. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... using the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental ... implants. A common problem encountered when patients have ... of sufficient bone volume to house the implant. Consequently there ... bone substitute until the natural bone regenerates. The bone substitute ...
(Date:6/18/2013)... 18, 2013 The "Bioinformatics Market By Sector ... Management Tools & Data Analysis Services) & Application (Genomics, Proteomics ... Major Market Drivers, Restraints, and Opportunities in North ... Asia-Pacific and Rest of World. Browse ... 22 Figures 364 Pages ...
(Date:6/18/2013)... 2013 Research and ... addition of the "Injectable Drug Delivery ... Devices [Disposables & Reusable, Fillable & Prefilled, ... Therapeutics [Diabetes & Oncology] - Global Forecasts ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ...
(Date:6/18/2013)... 2013 Inflamax Research Inc., a ... and Phase I-IV clinical trials, announced today that ... Air Environmental Technologies (NAET), a specialty air conditioning ... and servicing of mobile Environmental Exposure Chambers (EECs) ... , Inflamax Research has proprietary ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... EUSA,s Focus on Late-Stage and Marketed ... ... Pennsylvania and OXFORD, England, May 1 ,EUSA Pharma Inc (,EUSA,), ... critical care, today announced that,it has divested its monoclonal antibody ...
... in Milan and Northeast Georgia Medical Center in ... Gainesville, Stereotaxis to ... ... May 1 Stereotaxis, Inc. (Nasdaq:,STXS) announced today the first ever bi-directional live case ...
... April 30 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... Morgan Stanley Global Healthcare Unplugged Conference in Key,Biscayne, FL ... / 12:00 p.m. PT.,Previously, the presentation had been scheduled ... Bradbury, President and Chief Executive Officer of,Amylin Pharmaceuticals, will ...
Cached Biology Technology:EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network 2Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network 3Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network 4
(Date:6/18/2013)... 2013 The herbal extract of a yellow-flowered mountain ... increase the lifespan of fruit fly populations by an ... , But it,s how Rhodiola rosea ... grabbed the attention of study leaders Mahtab Jafari and ... in a manner completely unrelated to dietary restriction and ...
(Date:6/17/2013)... Boston, MA Women in the U.S. exposed to high ... as likely to have a child with autism as women ... new study from Harvard School of Public Health (HSPH). It ... autism and air pollution across the U.S. , "Our findings ... of the women in our study lived in areas where ...
(Date:6/17/2013)... professors in Wayne State University,s Department of Physics ... Research Experience for Undergraduates (REU) program. This program ... cutting-edge research in astrophysics, and in particle and ... Ph.D., professor of physics in Wayne State,s College ... director of the grant, the student participants will ...
Breaking Biology News(10 mins):Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2Wayne State welcomes undergraduates from around the US for physics research experience 2
... that differences in bacterial colonization of the infant gut in ... of genes involved in the infant,s immune system. The ... open access journal Genome Biology , is an Editor,s ... Illinois, Texas A&M University, Miami University, and University of Arkansas ...
... scientists from the National University of Singapore,s (NUS) Department of ... compound a compound that is undergoing preclinical trials as ... and stop them from growing into a tumour. This drug-led ... time a research group has provided evidence showing how a ...
... A clear change in salinity has been detected ... in the global rainfall and evaporation cycle., In a ... scientists from the Commonwealth Scientific and Industrial Research Organisation ... changing patterns of salinity in the global ocean during ...
Cached Biology News:Breast-fed babies' gut microbes contribute to healthy immune systems 2Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2Earth's water cycle intensifying with atmospheric warming 2
Moue Serum 8-12 Weeks Old...
Request Info...
... • Mouse serum is collected off the clot fasted ... of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: K3EDTA ...
Recombinant Mouse Wnt-3a...
Biology Products: